Search Videos by Topic or Participant
Browse by Series:

Maintenance Nab-Paclitaxel in Squamous NSCLC

Discussant: H. Jack West, MD
Published: Tuesday, Jul 29, 2014
For High-Definition, Click
The abound study is exploring maintenance therapy with nab-paclitaxel in patients with squamous cell non-small cell lung cancer (NSCLC). Maintenance strategies using pemetrexed are commonly used for patients with non-squamous histology; however, the abound trial hopes to discover a similar approach for patients with squamous histology, notes H. Jack West, MD.

Nab-paclitaxel is an attractive choice for maintenance therapy due to its favorable toxicity profile, suggests West. In the abound study, 4 cycles of induction therapy with nab-paclitaxel and carboplatin will be followed by maintenance nab-paclitaxel or best supportive care. The primary outcome measure will be progression-free survival.

Traditionally, maintenance therapy has been administered once every 3 weeks. In abound, nab-paclitaxel will be administered on day 1 and 8 of a 21-day cycle. Given this dosing strategy, it will be interesting to see whether fatigue, neuropathy, and cytopenias arise in the study, notes West. 
Slider Left
Slider Right
For High-Definition, Click
The abound study is exploring maintenance therapy with nab-paclitaxel in patients with squamous cell non-small cell lung cancer (NSCLC). Maintenance strategies using pemetrexed are commonly used for patients with non-squamous histology; however, the abound trial hopes to discover a similar approach for patients with squamous histology, notes H. Jack West, MD.

Nab-paclitaxel is an attractive choice for maintenance therapy due to its favorable toxicity profile, suggests West. In the abound study, 4 cycles of induction therapy with nab-paclitaxel and carboplatin will be followed by maintenance nab-paclitaxel or best supportive care. The primary outcome measure will be progression-free survival.

Traditionally, maintenance therapy has been administered once every 3 weeks. In abound, nab-paclitaxel will be administered on day 1 and 8 of a 21-day cycle. Given this dosing strategy, it will be interesting to see whether fatigue, neuropathy, and cytopenias arise in the study, notes West. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x